In the 41-patient pilot study released on Tuesday, for three of 21 patients who received the drug, AXA1125, their physical fatigue scores returned to normal levels after 28 days of treatment, Axcella Chief Medical Officer Margaret Koziel said in a phone interview.
“This trial is suggesting that a drug that’s very safe to take and has minimal side effects is causing substantial improvement in people’s physical and cognitive experience of fatigue,” said Dr. Jason Maley, a consultant for Axcella who runs a long COVID clinic at Beth Israel Deaconess Medical Center in Boston.Article content
For the study’s primary goal, there was no statistically significant difference between the groups on phosphocreatine recovery time.
Ivermectin also helps but that's not a Pfizer medication
Brought to you by Pfi$er.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CTVNews - 🏆 1. / 99 Read more »